FOR RELEASE THURSDAY, MARCH 26, 2015
BRIDGEWATER, NJ – Bausch + Lomb, a leading global eye health company, today announced the availability of an enhanced BLIS™ Injector System, which is designed exclusively for use with the enVista®, hydrophobic acrylic intraocular lens (IOL). With the new enhancements, eye care practitioners will be provided even greater control, allowing safe delivery of the enVista IOL through unenlarged phaco incisions as small as 2.2 mm.
The BLIS injector system was first introduced in February 2014 and features a reusable hand piece made of high-quality, titanium material designed for both reliability and comfort. The proprietary disposable cartridge is designed for easy lens loading and wound entry and smooth delivery of enVista. The enhanced BLIS now includes a softened and tumble-polished plunger tip that is 2mm longer than the previous design, which helps facilitate easier placement in the capsular bag, in addition to several other features to ensure a seamless, positive customer experience.
Bausch + Lomb collaborated with a number of surgeons and technicians around the country to enhance the functionality and design of the BLIS injector system.
“As a surgeon who has implanted a substantial number of enVista IOLs using BLIS, it was great to work seamlessly with Bausch + Lomb to further enhance and develop the next-generation BLIS injector system,” said Anil M. Shivaram, M.D. “With the upgraded features in BLIS, I look forward to using this enhanced system with the enVista IOL.”
The enVista hydrophobic acrylic IOL is the first and only FDA-approved IOL in the U.S. with labeling that states: “No glistenings of any grade were reported for any subject at any visit in the clinical study”.1 Glistenings are fluid-filled microvacuoles that can form within an IOL, and are common in some hydrophobic acrylic IOLs. They cause a portion of the light coming into the eye to be scattered in all directions, and have been shown to have a negative impact on visual acuity.2 Additionally, the enVista lens is designed to minimize Posterior Capsular Opacification (PCO), a common post-surgical complication with IOLs that cause vision to become clouded post-surgery.
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments. We globally develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries.
1. Bausch & Lomb Incorporated. Data on file, 2009.
2. Christiansen G, et al. Glistenings in the AcrySof intraocular lens: pilot study. J Cataract Refract Surg. 2001;27:728-33
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.